PURDUE’S ONE HEALTH AND WELL-BEING RESEARCH EVENT

Dan Golden, Ph.D.

Vice President of Global R&D Strategy and Research & Discovery Elanco Animal Health

Dr. Daniel Golden currently serves as the Vice President of Global R&D Strategy and Research & Discovery at Elanco Animal Health. He is responsible for overseeing the global R&D portfolio strategy, R&D operational strategy and all discovery activities of the Elanco pipeline to ensure a consistent flow of high-impact innovation in key markets.  This includes the global R&D portfolio from discovery through life-cycle management, the operational strategy for global R&D and target identification and new molecule creation.  His discovery team works across all species and technology areas, including – pharmaceuticals, biopharmaceuticals and vaccines. Dr. Golden is passionate about cultivating teams where productivity and creativity of thought are equally valued and relentlessly pursued.
 
Dr. Golden joined Elanco in 2015 as Director of Global Swine Pharmaceutical & Biopharmaceutical product development and has held multiple roles of increasing responsibility across the Research and Development and US Commercial organization, including direct-to-consumer retail and OTC product development. Prior to joining Elanco, Dr. Golden held several positions within Research and development at Merial Animal Health.
 
Dr. Golden graduated from Auburn University with a B.S. in Microbiology. He earned his Ph.D. in Biochemistry & Molecular Genetics at the University of Alabama School of Medicine in Birmingham. Dr. Golden’s doctoral research was in the biochemistry and molecular biology of African Trypanosomes, then moved to Northwestern University for postdoctoral research in RNA interference (RNAi). He was awarded both a National Research Service Award from the National Institutes of Health and a fellowship from the American Cancer Society.
 
Dr. Golden’s research is published in peer reviewed journals and has been featured in multiple international conferences. He currently is a member of the American Association for Advancement of Science and serves as a Board Member for the Indiana Biomedical Research Institute and BioCrossroads, an organization focused on growing Indiana’s vibrant biotechnology industry.

Wendy Srnic, Ph.D.

Vice President, Biotechnology Corteva Agriscience

Wendy leads the Biotechnology organization for Corteva Agriscience. In this role, she is responsible for the discovery and development of Corteva’s Biotechnology and Gene-edited product pipeline, global genotyping, and genomics to accelerate breeding, and novel enabling technologies. She and her team lead the Biotechnology strategy, execution, science, capability development, scientists, laureates, and facilities including laboratories, greenhouse, and controlled environments. Wendy earned her B.S. degree in Crop and Soil Science at Michigan State University, an M.S. degree in Weed Science from Virginia Tech, and her Ph.D. in Crop Science from North Carolina State University. She spent the first 7 years of her career in Europe (United Kingdom and Italy) before returning to the US. Wendy has 2 granted US patents and 24 external publications. She serves on the Board of Trustees for Grand View University in Des Moines, Iowa, and the Board of Directors for the Indiana Biosciences Research Institute. Wendy developed a passion for agricultural research growing up on her family’s farm in Michigan. She enjoys gardening, volunteering, running, travelling, and being with her four children and husband.

Matt von Zirkelbach

Vice President and Site Head of Lilly Medicine Foundry Eli Lilly and Company

Matt von Zirkelbach serves as Vice President and Site Head responsible for the design, build, and delivery of the Lilly Medicine Foundry, Lilly’s largest single Development investment in its history.  This entails innovating across all processes and functions to deliver a facility capable of producing nearly any technology in Lilly’s pipeline of innovation at clinical scale as well as the nexus of next-generation capabilities and talent.
 
Matt holds Bachelor of Science degrees in Biological Sciences & Health Sciences from Purdue University as well as a Master of Science in Engineering from Rose-Hulman Institute of Technology.  Before his current role, Matt led Strategy and Operations for Lilly’s Molecule Discovery organization as well as managing the Talent Development Academy across R&D.  This entailed building the organization’s long-term strategy, organizing and prioritizing scientific efforts, collaborating with external partners and designing systems to enable innovation.
 
Prior to joining Lilly, Matt served in a multitude of capacities from his 17 years in industry.  These roles ranged from global capacities such as Quality oversight for the entire lifecycle for products to plant management and operations.  Additionally, functional experience is brought from technical transfer, operational excellence, commercial operations, data analytics, as well as global marketing.  Matt uses his broad background and experience base to support progress of treatments through discovery into the clinic while building high-performing organizations to advance these critical needs to patients.